Barclays Maintains Overweight on Macrogenics, Raises Price Target to $6
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Barclays analyst Etzer Darout maintains Macrogenics (NASDAQ:MGNX) with a Overweight and raises the price target from $4 to $6.
Barclays analyst Etzer Darout maintains Macrogenics (NASDAQ:MGNX) with a Overweight and raises the price target from $4 to $6.